Share on StockTwits

Stock analysts at Investec hoisted their target price on shares of Clinigen Group PLC (LON:CLIN) from GBX 497 ($8.31) to GBX 512 ($8.56) in a report issued on Wednesday. The firm currently has a “buy” rating on the stock. Investec’s target price points to a potential upside of 27.15% from the stock’s previous close.

CLIN has been the subject of a number of other recent research reports. Analysts at Peel Hunt raised their price target on shares of Clinigen Group PLC from GBX 690 ($11.53) to GBX 710 ($11.87) in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Numis Securities Ltd reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Wednesday. They now have a GBX 650 ($10.87) price target on the stock. Finally, analysts at N+1 Singer reiterated a “buy” rating on shares of Clinigen Group PLC in a research note on Wednesday. They now have a GBX 439 ($7.34) price target on the stock. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of GBX 592.20 ($9.90).

Clinigen Group PLC (LON:CLIN) opened at 428.919 on Wednesday. Clinigen Group PLC has a 1-year low of GBX 354.92 and a 1-year high of GBX 690.00. The stock’s 50-day moving average is GBX 378.4 and its 200-day moving average is GBX 469.7.

Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.